MInjie Wang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Minjie Wang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Inner Mongolia Medical University | China

Prof. Minjie Wang is an accomplished biomedical researcher with a strong scholarly record, reflected by an h-index of 6, 15 peer-reviewed documents, and 93 citations. His research focuses on the discovery and functional characterization of active substances from Traditional Chinese Medicine and Mongolian Medicine, with particular emphasis on the pathological mechanisms of cardiovascular and cerebrovascular diseases and the identification of therapeutic drug targets. A major theme of his work is the role of AMP-activated protein kinase (AMPK) in vascular inflammation, endothelial dysfunction, atherosclerosis, metabolic syndrome, and adipose tissue remodeling. His studies integrate advanced in vivo animal models—including atherosclerosis, myocardial ischemia-reperfusion injury, arrhythmia, and cerebral ischemia—with comprehensive in vitro approaches encompassing cell culture, molecular biology, immunohistochemistry, and biochemical analysis. Prof. Wang has published extensively in high-impact journals such as European Heart Journal, Cell Death & Disease, Frontiers in Microbiology, Acta Pharmacologica Sinica, and European Journal of Pharmacology, contributing significant insights into vascular biology, inflammation, metabolism, and translational pharmacology. His work also includes patented innovations related to AMPK activators for vascular inflammation and endothelial protection, underscoring both scientific depth and translational relevance.

 

Citation Metrics (Scopus)

10080

60

40

20

0

Citations
93

Documents
15

h-index
6

Citations

Documents

h-index


View Scopus Profile

Featured Publications

 

Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.

Yuanyuan Li | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Yuanyuan Li | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Guangdong Provincial Laboratory of Traditional Chinese Medicine | China

Author Profile

Scopus

🎓 Early Academic Pursuits

Dr. Li’s academic path began with an exceptional undergraduate performance in Chemistry at Jilin University. Her passion for science led her to pursue a Master’s degree in Analytical Chemistry and subsequently a Ph.D. in the same field, which she completed in July 2014 under the guidance of esteemed professor Zhang Shusheng. During her doctoral studies, she received comprehensive training in analytical techniques and developed a strong interest in practical applications related to food and environmental safety.

🏢 Professional Endeavors

In 2014, Dr. Li joined the School of Public Health at Jilin University as a faculty member. She steadily rose through the ranks to become a full professor and doctoral supervisor. Her responsibilities have included leading multiple high-level national projects, mentoring graduate students, and engaging in collaborative research across disciplines. She has become a pivotal figure in shaping the academic direction of the university’s public health research programs.

🔬 Contributions and Research Focus

Dr. Li’s research primarily focuses on food safety risk assessment, monitoring of toxic and hazardous substances in the food chain, and the development of advanced analytical methods. She has published over 80 high-impact academic papers, including articles in Analytical Chemistry, Biosensors and Bioelectronics, ACS Sensors, and TrAC Trends in Analytical Chemistry. Her work integrates innovative electrochemical and optical biosensing techniques, making significant advancements in the detection of pesticide residues, foodborne pathogens, and environmental pollutants.

🏆 Accolades and Recognition

Her excellence has not gone unnoticed. Dr. Li has received several prestigious honors, including the “Young Elite Scientists Sponsorship Program” by the China Association for Science and Technology and the First Prize for Scientific and Technological Progress by the Jilin Provincial Government. She has also served as a visiting scholar at the University of Michigan, where she broadened her international research collaboration network.

🌍 Impact and Influence

Dr. Li's research has had a profound impact on public health, food regulation, and environmental policy. Her cutting-edge methodologies contribute directly to national standards and have been implemented in real-world food safety monitoring. She is also an active member of professional organizations and frequently serves as a reviewer for top-tier scientific journals, thereby shaping the future of analytical science and public health on both national and global scales.

🔮 Legacy and Future Contributions

Looking forward, Dr. Yuanyuan Li is poised to continue her groundbreaking work in biosensor development and integrated health risk assessment. Her vision is to establish more comprehensive detection platforms that can safeguard food and environmental quality, ultimately enhancing public health resilience. As a mentor, researcher, and innovator, her legacy is one of rigorous science combined with a deep commitment to societal well-being.

 

Publications

📄 Shenxiong Yixin Decoction polysaccharides exert therapeutic effects against myocardial ischemia-reperfusion injury via intestinal exosomal microRNA-21 regulation

Authors:
De-Sheng Xu, Yan Wang, Zi-Rui Li, Ping-Li Mo, Ming-Tai Chen, Rui-Zhi Zhao, Zheng Fan, Wen-Jie Mo, Qi-Lu Li, Fang-Cao Pi, Qi-Di Sun, Juan-Min Li, Yun-Da Yao, Jian-Ping Chen, Yuan-Yuan Li, Jie-Nan Luan, Shang-Bin Zhang, Ying Xie, Hua Zhou

Journal: Pharmacological Research   Year: 2025

📄 Syringic acid attenuates acute lung injury by modulating macrophage polarization in LPS-induced mice

Authors:
W.-T. Wang, Y.-Y. Zhang, Z.-R. Li, J.-M. Li, H.-S. Deng, Y.-Y. Li, H.-Y. Yang, C.-C. Lau, Y.-J. Yao, H.-D. Pan, L. Liu, Y. Xie, H. Zhou et al.

Journal: Phytomedicine   Year: 2024

📄 A classical herbal formula alleviates high-fat diet induced nonalcoholic steatohepatitis (NASH) via targeting mitophagy to rehabilitate dysfunctional mitochondria, validated by UPLC-HRMS identification combined with in vivo experiment

Authors:
M.-T. Chen, F.R. Huang, B.-H. Chen, J.-L. Kang, Y.-J. Yao, M.-N. Liu, Y.-Y. Li, Y.-Q. Li, T.-R. Zhou, D.-T. Peng, L.-D. Luo, C.-S. Wei, Y.-F. Xing, Q.-B. Wu, H. Zhou, G.-D. Tong

Journal: Biomedicine & Pharmacotherapy   Year: 2023